Mateon Therapeutics to initiate commercialization of COVID-19 Ayurveda med in India

Mateon Therapeutics has announced that ArtiShield is now approved for manufacture and marketing by the Ministry of AYUSH, for the treatment of various symptoms like fever and inflammation. ArtiShield is in co-development with Windlas Biotech, Mateon’s commercial partner for India. ArtiShield is being evaluated against COVID-19 in ARTI-19- a phase IV study in India. ArtiShield is the Ayurveda – DvipaantaraDamanaka- and is labelled as capsule containing Artemisia absinthium Powder 500mg.

Related posts:

AIIA collaborates with Nisarga Herbs to conduct India’s first clinical trial on prevention of Covid-19 with Neem capsules 210-bedded Ayush Covid care centre in Mysuru Dalmia Healthcare Starts Clinical Trial with its Ayurvedic Composition to Treat COVID-19 Government plans to set up All India Institute of Ayurveda on Konkan coastline Ayurveda, social enterprises courses attract New Zealand students to India